Please login to the form below

Not currently logged in
Email:
Password:

opioid addiction

This page shows the latest opioid addiction news and features for those working in and with pharma, biotech and healthcare.

FDA awards another non-opioid pain drug breakthrough status

FDA awards another non-opioid pain drug breakthrough status

FDA awards another non-opioid pain drug breakthrough status. Second drug fast-tracked amid addiction epidemic. ... The FDA is prioritising the approval of new non-opioid pain treatments, as part of the US battle against its opioid addiction epidemic.

Latest news

  • Regeneron and Teva close gap on rivals with NGF pain drug Regeneron and Teva close gap on rivals with NGF pain drug

    Nevertheless, fasinumab and tanezumab are now leading what analysts consider could be a highly-lucrative market for drugs that deliver effective pain relief without the risk of side effects and addiction ... In contrast to opioids, which alter pain

  • Indivior push to diversify boosted by schizophrenia drug approval Indivior push to diversify boosted by schizophrenia drug approval

    For years, Indivior has made the bulk of its revenues from opioid addiction treatment Suboxone. ... Perseris is a key product in Indivior’s diversification plans, along with newer painkiller addiction therapy Sublocade (long-acting buprenorphine) which

  • Heron boosted by new data for ‘breakthrough’ pain drug Heron boosted by new data for ‘breakthrough’ pain drug

    opioid analgesics compared to both placebo and local anaesthesia monotherapy with bupivacaine in the first 48 hours after surgery. ... The reduction in opioid use is another important facet of the new therapy, given the US’s current epidemic of opioid

  • The year of the blockbuster The year of the blockbuster

    The diseases targeted by the report’s projected market entrants include type 2 diabetes, endometriosis, childhood epilepsy, haemophilia, HIV, migraine, opioid addiction and shingles. ... Sublocade (buprenorphine) from Indivior:Sublocade, having been

  • Alkermes slumps as FDA turns down depression drug Alkermes slumps as FDA turns down depression drug

    The US regulator issued a ‘refusal to file’letter to the company yesterday for the drug, which is a fixed-dose combination of buprenorphine, an opioid used for many years to ... treat addiction, and samidorphan, a new mu-opioid receptor antagonist.

More from news
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics